
The National Pancreatic Cyst Registry Study1,4
- Integrated Molecular Pathology (PancraGEN®) is intended to be an adjunct to first line testing
- When used as adjuvant to EUS/FNA testing, PancraGEN® can reduce the number of unnecessary surgeries while also providing assurance in surveillance strategies of patients
- Real world intervention and surveillance decisions were highly associated with PancraGEN® diagnostic recommendation
- PancraGEN® diagnoses were more predictive of real world management decisions, benefiting overall patient outcomes more than sole reliance on ICG criteria